top of page


FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy
The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.

nuaxia
6 hours ago2 min read


Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.

nuaxia
Oct 232 min read


FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.

nuaxia
Oct 222 min read


FDA approves Gazyva for idiopathic nephrotic syndrome in patients aged two years and older
The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

nuaxia
Oct 12 min read


FDA approves Kerendia for chronic kidney disease associated with type 1 diabetes
The FDA has expanded the approved use of Kerendia to adults with chronic kidney disease associated with type 1 diabetes, introducing a new treatment option for this high-risk population.

nuaxia
Sep 182 min read


US Nephrologist Compensation Reaches $385,965 in Doximity’s 2026 Report
Average annual compensation for US nephrologists reached $385,965 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in nephrology.

nuaxia
Sep 73 min read


Prospective study reports sustained outcomes with Elizaria in atypical haemolytic uraemic syndrome
The 56-week observational findings add longer-term clinical evidence for the eculizumab biosimilar in both complement-inhibitor-naive patients and those previously treated with reference eculizumab.

nuaxia
Jul 302 min read
bottom of page